Tokenized Thulium by Toto Finance
The Element Replacing the Scalpel. 4.2 Tonnes a Year. 450,000 Surgeries and Counting. Now On-Chain.
Somewhere in a surgical suite right now, a urologist is vaporizing a kidney stone with a beam of light instead of cutting a patient open. That beam is generated by a thulium fiber laser operating at 1.94 to 2.0 micrometers, a wavelength so precisely absorbed by water in soft tissue that it ablates with minimal thermal damage and superior hemostasis compared to any alternative. Thulium made that possible. And the world produces 4.2 tonnes of it per year. That is not a typo. The entire annual global supply of the element revolutionizing minimally invasive surgery, powering portable X-ray devices for field hospitals, enabling next-generation superconductors for quantum computing, and providing radiation sources for industrial inspection would fit in the trunk of a car. Thulium is the second-rarest stable rare earth element, constituting just 0.007% of monazite sand. China controls 91% of production. Demand is growing at 32% annually from medical lasers alone. And the 8.5-tonne supply gap projected for 2030 means a world where surgical suites compete for grams of an element that most people have never heard of. Toto Finance is building the infrastructure to bring the surgeon's element on-chain for the first time, from 1:1 redeemable refined oxide to In-Ground future delivery contracts, settled instantly in stablecoins with full DeFi secondary market access.
THE WHY
The Surgical Revolution Running on an Element the World Produces in Single-Digit Tonnes.
We chose thulium because it represents the collision between a medical technology revolution that is transforming patient outcomes and a supply reality that cannot sustain it.
Thulium fiber lasers are replacing conventional surgical instruments across urology, oncology, dermatology, and pulmonology because they offer something no scalpel, no electrocautery device, and no competing laser wavelength can match: tissue ablation at 1.94 to 2.0 micrometers with near-perfect water absorption, delivering precise cutting with immediate hemostasis and minimal collateral thermal damage. Urologists performing kidney stone fragmentation, prostate enucleation, and bladder tumor resection are adopting thulium lasers at 32% annual growth because patient outcomes are measurably superior. But every fiber laser system contains 30 to 80 grams of thulium-doped fiber. And the world produces 4.2 tonnes of thulium per year. Total. For every application. That is barely enough to supply two major medical laser manufacturers' annual production, before accounting for portable X-ray devices, industrial radiation sources, superconductor research, and every other application drawing from the same microscopic supply pool. Thulium constitutes 0.007% of monazite sand, the second-lowest concentration of any stable lanthanide. China produces 91% of it. There is no mechanism on Earth to scale thulium supply independently of other heavy rare earth production, and the surgical revolution consuming it is accelerating faster than any mine can respond.
That is why we exist.
4.2 tonnes
An Entire Year's Production Fits in a Car Trunk
Global thulium production is approximately 4.2 tonnes annually, nearly all of it recovered as a minor byproduct during heavy rare earth separation at Chinese ion-adsorption clay processing facilities. Thulium is the second-rarest stable lanthanide, present at just 0.007% in typical monazite sand, roughly 50 times less abundant than neodymium within the same ore bodies. This extreme geological scarcity means that even dramatic expansion of rare earth mining increases thulium supply by only kilograms, not tonnes. Roskill forecasts a 1.8-tonne deficit in 2025, a shortfall that represents 43% of current production capacity.
2.0 μm
The Wavelength That Replaced the Scalpel
Thulium fiber lasers emit at 1.94 to 2.0 micrometers, a wavelength near the peak absorption coefficient of water in biological tissue. This means the laser energy is absorbed within a superficial layer of tissue, creating precise ablation with immediate coagulation and minimal thermal penetration into surrounding structures. No other rare earth laser, including holmium at 2.1 μm, achieves this combination of precision and hemostasis at the power levels required for urological surgery. 85% of global thulium consumption is driven by medical fiber laser manufacturing, a sector growing at 32% compound annual growth rate.
8.5 tonnes
A Deficit Measured in Grams per Surgical System
Global thulium demand is projected to reach 21 tonnes per year by 2030, while supply from existing and planned rare earth operations will deliver approximately 12.5 tonnes. The 8.5-tonne gap represents a 40% shortfall. Each thulium fiber laser system consumes 30 to 80 grams of the element. With 450,000 thulium laser procedures performed annually and growing, the cumulative demand from medical devices alone will consume the majority of global production, leaving portable X-ray, superconductor, and industrial applications to compete for an ever-shrinking remainder.
THE ELEMENT
Understanding Why Thulium Powers Surgical Precision That No Other Element Can Deliver
The second-rarest stable lanthanide. The fiber laser wavelength that tissue absorbs perfectly. The portable radiation source that brings diagnostics to battlefields and disaster zones. Produced at 4.2 tonnes per year.
Tm
- Atomic Number: 69
- Density: 9,320 kg/m³
- Melting Point: 1,545°C
- Ore Concentration: 0.007% in Monazite
- Classification: Second-Rarest Stable Lanthanide
The Element
Where It Comes From
Thulium is recovered as a minor byproduct during heavy rare earth separation, primarily from ion-adsorption clay deposits in southern China (Jiangxi, Fujian, Guangdong) and secondarily from xenotime, monazite, and euxenite ores in Australia, Brazil, and the USA. At 0.007% concentration in typical monazite sand, thulium is approximately 50 times less abundant than neodymium within the same deposits. China produces 91% of global output. Total annual production: 4.2 tonnes, making thulium's supply entirely dependent on heavy rare earth processing decisions driven by elements that are far more abundant.
Ore / Clay → Leaching → Chemical Separation → Multi-Stage Ion Exchange → Heavy Rare Earth Fractionation → Precipitation → 99.9% Pure Thulium Oxide (Tm₂O₃)
The Physics That Make Surgeons Choose Thulium
Thulium's Tm³⁺ ions emit at 1.94 to 2.0 micrometers when excited in fiber or crystal host materials, a wavelength absorbed by water with an absorption coefficient roughly ten times higher than holmium's 2.1 μm emission. This creates precise, superficial tissue ablation with immediate hemostasis. Thulium-170, a radioactive isotope with a 128-day half-life, emits low-energy gamma radiation (84 keV) ideal for portable X-ray devices that require no electrical power source. Thulium also exhibits bright blue luminescence from Tm³⁺ transitions, becomes ferromagnetic below 32K, and forms high-temperature superconducting compounds (TBCO) for quantum computing research.
Where It Goes
Thulium fiber laser surgical systems (urology, oncology, dermatology, pulmonology), Tm:YAG solid-state lasers for military range-finding and materials processing, Tm-170 portable X-ray devices for field hospitals and disaster response, industrial radiography for non-destructive weld and structural testing, thulium-barium-copper-oxide (TBCO) high-temperature superconductors, quantum computing cryogenic components, anti-counterfeiting UV luminescent markers for currency and documents.
$28M+ global thulium market (85% consumed by medical laser applications, growing 32% annually)
THE CATALYST
Surgeons Are Adopting Thulium Lasers at 32% Annual Growth. The World Produces Enough Thulium for a Fraction of Them.
The medical technology industry does not adopt new surgical platforms at 32% annual growth unless patient outcomes compel it. Thulium fiber lasers are not a marginal improvement over existing surgical tools. They are a generational shift in how urologists treat kidney stones, how oncologists resect tumors, and how dermatologists ablate tissue. The clinical evidence is unambiguous: superior hemostasis, reduced thermal damage, faster recovery. Hospitals are purchasing thulium laser systems as fast as manufacturers can build them. And the manufacturers are constrained not by engineering or demand but by an element the world produces at 4.2 tonnes per year, of which 3.5 tonnes is already consumed by medical fiber laser production. The remaining 700 kilograms must serve every other application on Earth that requires thulium.
Thulium Fiber Lasers: The Surgical Platform That Consumes 85% of Global Supply
Thulium fiber lasers are revolutionizing urological surgery, delivering superior kidney stone fragmentation, prostate enucleation, and bladder tumor resection compared to holmium laser alternatives. With 450,000 thulium laser procedures performed annually and growing at 32% compound annual growth rate, each laser system containing 30 to 80 grams of thulium-doped fiber, and major medical device companies (Olympus, Boston Scientific, Quanta System) expanding their thulium laser portfolios, medical fiber lasers consume approximately 3.5 tonnes of thulium annually. By 2030, medical laser demand alone is projected to require 15 tonnes, exceeding current total global production by more than three times.
Portable X-Ray Systems: Diagnostics Where Hospitals Cannot Reach
Thulium-170 isotopes (128-day half-life, 84 keV gamma emission) enable compact, portable X-ray devices that require no electrical power source, operating from radioactive decay alone. Military field hospitals, disaster response teams, remote clinics, and veterinary practices deploy Tm-170 portable imaging where conventional X-ray infrastructure is impossible. Each portable unit requires 5 to 15 grams of thulium-170. The sector consumes approximately 0.4 tonnes annually, growing at 28% compound annual growth rate as point-of-care diagnostics expand across conflict zones, humanitarian operations, and underserved healthcare systems worldwide.
Industrial Radiography: Inspecting What Eyes Cannot See
Thulium-170 radiation sources power non-destructive testing (NDT) of welds, castings, and structural components in aerospace, oil and gas, nuclear, and construction industries. The element's low-energy gamma emission provides ideal penetration depth for thin-to-medium section radiography with superior image contrast compared to iridium-192 for certain applications. Industrial NDT consumes approximately 0.2 tonnes annually, with demand growing as infrastructure inspection requirements intensify across aging pipeline networks, offshore platforms, and nuclear facilities.
Superconductors and Quantum Computing: Thulium at the Frontier of Physics
Thulium-barium-copper-oxide (TBCO) compounds achieve superconductivity above liquid nitrogen temperatures (77K), making thulium a material of active research for next-generation MRI magnets, particle accelerators, and quantum computing cryogenic infrastructure. Research institutions and quantum hardware developers consume approximately 0.1 tonnes annually, projected to reach 1.5 tonnes by 2030 as quantum computing transitions from laboratory prototypes to commercial deployment and TBCO superconductors advance toward industrial application.
A Medical Revolution Outrunning Its Own Material Supply
Bar chart showing global thulium demand rising from 6.0 tonnes in 2025 to 21.0 tonnes by 2030, with supply reaching approximately 12.5 tonnes, creating an 8.5-tonne annual deficit representing 40% of projected demand.
2025
6.0 t
Demand
2028
12.5 t
Demand
2030
21.0 t
Demand
2035
38.0 t
Roskill projection
2030 Supply
~12.5 t
Gap: 8.5+ t (40%)
Sources: Roskill, Critical Minerals Intelligence, USGS, American Urological Association.
TWO PRODUCTS
Two Ways to Own Tokenized Thulium
Everything we believe about opening access to the element that is transforming how surgeons operate, how field hospitals diagnose, and how the world inspects its critical infrastructure comes to life in two products. One for thulium oxide that has already been separated, purified, and vaulted. One for thulium still locked in heavy rare earth deposits awaiting extraction. Both backed by physical material. Both settleable in stablecoins. Both built to give the medical device manufacturers, radioisotope producers, superconductor researchers, and investors who understand that 4.2 tonnes per year cannot sustain a surgical revolution growing at 32% annually a way to secure the element that is redefining minimally invasive medicine.
1:1 Thulium Oxide Token
Digital ownership of physical thulium. Every token is backed 1:1 by refined thulium oxide (Tm₂O₃) in insured, audited vault facilities. High-purity grade (99.9%+ Tm₂O₃), ready for medical fiber laser doping, Tm-170 radioisotope target preparation, Tm:YAG crystal growth, and superconductor compound synthesis. Redeemable for physical thulium on demand. Not a derivative. Not a rare earth basket. Not a mining equity. The actual oxide, at medical-application purity.
- Backed 1:1 by refined thulium oxide (99.9%+ Tm₂O₃ purity grade)
- Always redeemable for physical thulium delivery on demand
- Stored in insured, independently audited vault and warehouse facilities
- On-chain proof-of-reserves with real-time oracle feeds
- Fractional ownership, from $1, tradeable 24/7 with instant stablecoin settlement
- Ready for industrial end-use: medical fiber laser doping, Tm-170 portable X-ray sources, Tm:YAG solid-state lasers, TBCO superconductors, industrial radiography, anti-counterfeiting markers
In-Ground Thulium
Forward positions in thulium that has not been separated yet. Tokenized future delivery contracts backed by proven thulium content in heavy rare earth deposits at certified mining operations. For organizations that understand that an element constituting 0.007% of monazite sand and produced at 4.2 tonnes annually is facing a surgical technology adoption curve growing at 32% per year, creating a supply arithmetic where medical laser demand alone will exceed total global production before the end of the decade.
- Backed by proven thulium content in heavy rare earth reserves at partner mining sites
- Pre-production pricing reflecting extreme geological scarcity and medical demand acceleration
- On-chain reserve tracking with geological data transparency
- Physical delivery or settlement at maturity
- Verified reserves with third-party geological audits
- Built for medical device manufacturers, radioisotope producers, sovereign funds, superconductor developers, and institutional allocators
SHORT-TERM DELIVERY
1 to 12 Months
Near-term thulium delivery contracts tied to active rare earth operations with heavy rare earth separation capacity. For medical device companies managing laser system production schedules, radioisotope producers coordinating Tm-170 target fabrication, and commodity specialists positioning in a market where a single large medical device order can absorb a significant fraction of available global supply and where 85% of production is already consumed by one application sector.
LONG-TERM DELIVERY
1 to 6 Years
Multi-year thulium positions backed by proven heavy rare earth content at earlier-stage mining operations. Built for sovereign healthcare supply reserves, medical device OEMs planning decade-scale surgical laser production, quantum computing companies securing superconductor feedstock, and institutional allocators who understand that thulium's supply deficit is the consequence of a 0.007% ore concentration colliding with the fastest-growing surgical technology adoption curve in modern urology.
SOURCING
Securing the Rarest Stable Rare Earth on Earth. From Every Heavy Rare Earth Source That Produces It.
Thulium is one of the least abundant lanthanides in the Earth's crust, present at just 0.007% in typical monazite sand and recoverable only during the final fractionation stages of heavy rare earth separation. Its production is entirely dependent on the processing decisions of facilities whose primary products are yttrium, dysprosium, terbium, and other heavier lanthanides. Toto Finance works directly with rare earth mining companies and heavy rare earth separation facilities across every production pathway, securing thulium at the point of final-stage fractionation where it transitions from a minor constituent in mixed heavy rare earth concentrate to a purified, individually valuable medical-grade oxide.
China
China produces 91% of global thulium from ion-adsorption clay deposits across Jiangxi, Fujian, and Guangdong provinces. Chinese heavy rare earth separation facilities in these regions perform the multi-stage ion exchange processing required to isolate thulium from the other 16 rare earth elements. Chinese export controls and production quotas are tightening availability for international medical device supply chains at the exact moment surgical laser adoption is accelerating globally.
North America (United States and Canada)
US heavy rare earth development includes Round Top (Texas), Bear Lodge (Wyoming), and projects targeting ion-adsorption clay analogs with heavy rare earth fractionation capability. Canadian projects in Quebec and Saskatchewan are developing heavy rare earth separation infrastructure. Critical mineral designations and defense/medical supply chain security initiatives are accelerating domestic thulium separation capacity for medical device and radioisotope applications.
Australia
Australia hosts thulium-bearing heavy rare earth deposits in xenotime mineral sands and clay formations across Northern Territory and Western Australia. Advanced hydrometallurgical separation technologies enable economic thulium recovery from ores where the element's extreme scarcity has historically made extraction uneconomical. Australian operations represent a strategic source for allied medical device supply chains.
Southeast Asia and Vietnam
Vietnam's ionic clay deposits in the northern highlands contain heavy rare earth concentrations including thulium. Emerging Southeast Asian processing facilities are developing specialized heavy rare earth fractionation capabilities, creating alternative thulium supply pathways outside the Chinese processing monopoly for medical laser and radioisotope manufacturers.
Greenland and Scandinavia
Greenland's Kvanefjeld project and Scandinavian rare earth deposits (Norra Kärr in Sweden) contain heavy rare earth content including thulium. Strategic importance for European medical device manufacturers and scientific research institutions seeking non-Chinese sourcing for an element critical to the continent's surgical technology and quantum computing research programs.
Exploration and Development
New heavy rare earth projects across Africa (Tanzania, Burundi, Madagascar), South America (Brazil), and Central Asia are in exploration and feasibility stages. These represent the next generation of thulium supply. In-Ground Thulium positions offer access at pre-production economics before heavy rare earth fractionation output reaches the medical device market.
Secured at the final-stage fractionation point. Thulium does not come from a thulium mine. It emerges at the tail end of heavy rare earth separation, after yttrium, dysprosium, terbium, and other heavier lanthanides have been extracted, in quantities measured in kilograms per processing batch. Toto Finance works at this critical final-stage fractionation point, partnering directly with heavy rare earth separators to secure thulium at the moment it becomes an individual medical-grade oxide rather than a trace constituent in mixed concentrate. Verified provenance. Transparent chain of custody from mine to operating room. Access to the element that is transforming surgery, one laser at a time.
PARTICIPANTS
Who Buys Tokenized Thulium
Thulium has never been accessible as an investment asset in any form. Its market is too small for an ETF (4.2 tonnes globally). Its production is too concentrated for a futures contract (91% China). Its applications are too specialized for commodity dealers to maintain inventory (medical-grade purity requirements). The medical device manufacturers and radioisotope producers that consume thulium have had no mechanism to secure forward supply independently, hedge thulium-specific price risk, or guarantee material availability for surgical laser production schedules. For an element consumed at 30 to 80 grams per laser system in a market growing at 32% annually, this absence of procurement infrastructure is not a market inconvenience. It is a constraint on how quickly a life-improving surgical technology can reach patients. Toto Finance creates that infrastructure for the first time.
The Companies Building the Surgical Tools That Save Lives
These buyers consume thulium to build the fiber laser systems that urologists use to treat kidney stones without open surgery, that oncologists use to resect tumors with precision impossible ten years ago, that dermatologists use to ablate tissue with minimal scarring. They also produce the Tm-170 portable X-ray sources that bring diagnostic imaging to conflict zones and disaster sites where patients would otherwise go undiagnosed. Tokenized thulium gives them supply assurance, forward procurement capability, and physical delivery infrastructure for an element that determines their production capacity and, downstream, patient access to better surgical outcomes.
Thulium fiber laser system manufacturers (Olympus, Quanta System, Lisa Laser), surgical equipment OEMs and medical device companies, urology and minimally invasive surgery device producers, Tm-170 portable X-ray and diagnostic imaging manufacturers, industrial radiography and NDT equipment producers, Tm:YAG solid-state laser manufacturers, nuclear medicine and radioisotope target producers, high-temperature superconductor developers (TBCO), quantum computing hardware and cryogenic system manufacturers, laser fiber and optical component manufacturers, anti-counterfeiting and security marking companies.
Investing in the Material Bottleneck Behind a 32%-Growth Surgical Technology
Medical technology investors evaluate market size, adoption curves, and competitive dynamics. They rarely examine the material supply chain beneath the technology. Thulium fiber lasers are growing at 32% annually, the fastest adoption rate of any surgical platform in urology, and 85% of global thulium production is consumed by this single application. When a surgical technology's growth rate outpaces its input material's production capacity by a factor of seven, the material becomes the bottleneck that determines how fast the technology scales. Tokenized thulium offers direct exposure to this bottleneck, with fractional access from $1 and a supply deficit that is widening with every laser system shipped.
Collateral Backed by the Element Behind the Fastest-Growing Surgical Technology on Earth
When an element's primary demand driver is a medical technology growing at 32% compound annual growth rate, consuming 85% of available supply, with clinical evidence compelling adoption across every major hospital system globally, the demand trajectory is not speculative. It is clinical. Tokenized thulium offers on-chain participants collateral backed by an element whose consumption is driven by patient outcomes rather than market sentiment: hospitals adopt thulium lasers because patients recover faster, not because commodity markets move.
Crypto funds seeking exposure to medtech-driven material demand uncorrelated to macroeconomic cycles, protocol treasuries diversifying into physical assets whose consumption is driven by clinical evidence rather than consumer discretion, DeFi protocols building collateral pools backed by elements at the supply bottleneck of high-growth medical technologies, blockchain foundations investing in the physical constraint behind surgical technology adoption, DAOs with healthcare technology and critical material investment mandates.
GLOBAL TRADE
Instant Settlement for Tokenized Thulium. No Specialty Dealers. No Medical Supply Chain Delays.
Thulium procurement operates through a microscopic market: a handful of Chinese heavy rare earth exporters, a few specialty commodity dealers internationally, and a medical device supply chain where material availability determines how many laser systems can be manufactured in a given quarter. Settlement timelines are measured in weeks. Pricing is opaque, varies by customer relationship, and changes with Chinese production quotas rather than international market demand. For a medical device manufacturer whose production schedule is constrained by thulium availability, waiting weeks for settlement of material measured in kilograms means surgical systems delayed, hospital orders unfilled, and patients waiting for procedures that technology has already made possible. We built what the medical rare earth supply chain needs.
The Old Way
Specialty Dealers. Weeks to Settle. Medical Supply Chain Bottleneck.
Settlement: T+5 to T+21 (standard for specialty heavy rare earth transactions)
The Toto Finance Way
Source ↔ Buyer. Direct. Instant.
Settlement: T+0 (Instant)
Thulium's market is so small that traditional commodity infrastructure has never been built for it. No exchange lists it. No clearing house processes it. No standardized contract exists. Medical device manufacturers procure thulium through personal relationships with a handful of specialty dealers who maintain minimal inventory and quote prices bilaterally. A surgical laser manufacturer's production capacity can be constrained by a single dealer's allocation decision. Toto Finance uses blockchain to create what the medical rare earth supply chain has never had: a transparent, continuous, instant-settlement market where thulium sources connect with medical device manufacturers, radioisotope producers, institutional investors, and qualified buyers through infrastructure designed for the precision and reliability that the surgical technology supply chain demands.
Settlement Calibrated to Surgical Precision
USDC
Circle
Fully reserved and independently attested dollar stablecoin engineered for institutional settlement. The compliance architecture and regulatory transparency that medical device manufacturers, hospital procurement systems, and sovereign healthcare supply programs require for auditable digital transactions involving materials that become components of Class II and Class III surgical devices.
USDT
Tether
Over $140 billion in global circulation providing settlement depth for an element whose entire annual global market trades in the tens of millions. USDT's liquidity infrastructure eliminates the counterparty friction of specialty dealer banking channels where a single delayed wire transfer can hold up a medical device manufacturer's quarterly production.
USAT
Tether (US Regulated)
US-regulated stablecoin under the GENIUS Act framework. Purpose-built for critical material procurement where FDA supply chain traceability expectations, Defense Production Act provisions for medical countermeasures, and US healthcare supply security mandates govern the acquisition of materials entering surgical device manufacturing.
SECONDARY MARKETS
DeFi Infrastructure for Tokenized Thulium
Thulium has never existed as a financial asset. Its market is too small for any traditional financial instrument. No ETF includes it as an identifiable holding. No futures contract references it. No commodity index tracks it. No lending facility recognizes it as collateral. The element that is reshaping minimally invasive surgery has been financially invisible for its entire commercial existence, traded through handshake deals between specialty dealers and medical device procurement teams. Tokenization does not merely digitize thulium. It creates thulium as a financial asset for the first time, constructing market infrastructure for an element whose medical importance vastly exceeds its financial recognition.
The First Thulium Market, Calibrated to the Surgical Technology Supply Chain
Before tokenization, thulium traded through phone calls between specialty dealers and medical device procurement managers. No continuous market. No visible pricing. No order book. No mechanism for price discovery beyond bilateral negotiation. Tokenized thulium creates the first open trading venue: a secondary market on decentralized exchanges where price discovery reflects real-time surgical laser production schedules, hospital adoption rates, and medical device manufacturing demand, making thulium's value visible to the financial system for the first time.
Yield Derived from the Material That Surgical Suites Cannot Operate Without
Lend thulium tokens to counterparties seeking leveraged exposure to medical rare earth pricing or hedged positions in surgical technology supply chains. Interest rates reflect real-world demand driven by thulium laser adoption curves, hospital capital expenditure cycles, portable X-ray deployment schedules, and quantum computing hardware development timelines. Yield generated by a material whose primary consumption driver is clinical evidence compelling surgical adoption, not cyclical market demand.
Capital Without Surrendering Positions in the Surgical Revolution's Material Bottleneck
Medical device manufacturers and institutional investors holding thulium positions have historically had no mechanism for accessing capital from those holdings, because thulium has never existed as a financial asset and its market has had zero secondary liquidity. Borrow against thulium tokens to receive stablecoins while maintaining full exposure to an element whose 32%-growth demand trajectory, 4.2-tonne production base, and 40% supply deficit create a fundamentally different value dynamic than any commodity with established production infrastructure.
Risk Architecture for an Element Whose Supply Is Measured in Single-Digit Tonnes
Thulium's supply risk is unique even among rare earths: 4.2 tonnes of annual production, 91% concentration in China, 0.007% ore concentration, and dependence on heavy rare earth processing decisions driven by more abundant elements. Traditional commodity risk models do not account for markets measured in tonnes rather than thousands of tonnes. Smart contract infrastructure automates collateral monitoring calibrated to micro-market dynamics, margin management reflecting the extreme price sensitivity of a 4.2-tonne market to individual large orders, and position tracking for an asset whose entire global supply can be materially affected by a single medical device manufacturer's procurement decision.
From Heavy Rare Earth Fractionation to Global Digital Market: The Thulium Token Path
Fractionated: Thulium oxide isolated during final-stage heavy rare earth separation, purified to 99.9%+ medical-application grade, secured in insured custody, and bound to on-chain token identity
Acquired: Purchased with USDC, USDT, or USAT at transparent pricing reflecting real-time surgical laser demand and heavy rare earth fractionation output
Positioned: Held in wallet, traded on secondary markets, or bridged across chains to integrate with holder procurement and portfolio infrastructure
Activated: Deployed into yield protocols, pledged as loan collateral, or structured for medical supply chain disruption hedging
Delivered: Redeemed for physical thulium oxide (Tm₂O₃, 99.9%+) for fiber laser doping, Tm-170 radioisotope target preparation, Tm:YAG crystal growth, or superconductor compound synthesis
WHY TOKENIZED
Tokenized Thulium vs Every Other Way to Get Exposure
There has never been a practical way to invest in thulium. No ETF tracks it. No futures exchange lists it. Specialty dealers trade it in kilogram lots through personal relationships with opaque pricing. Mining stocks bury thulium revenue beneath dominant light rare earth production. Toto Finance built what the medical rare earth market has never had: standalone, fractional, instant access to the element that powers the fastest-growing surgical technology in urology and the portable X-ray devices bringing diagnostics to the world's most underserved patients.
| Feature | Specialty Dealers | Toto Finance | Physical Thulium | Mining Stocks |
|---|---|---|---|---|
| Thulium-Specific | Yes (limited lots) | Yes (1:1) | Direct ownership | No (minor byproduct) |
| Trading Hours | Business hours only | 24/7/365 | Dealer availability | Market hours only |
| Settlement | T+5 to T+21 | T+0 (Instant) | Weeks to months | T+2 |
| Settlement Currency | Fiat (via dealer) | USDC, USDT, USAT | Wire transfer | Fiat (via broker) |
| Min. Investment | $150,000+ | Fractional (from $1) | $150,000+ | 1 share (~$10+) |
| Physical Redemption | By arrangement | Yes | Yes | No |
| On-Chain Transparency | No | Yes | No | No |
| DeFi Yield / Loans | No | Yes | No | No |
| Price Transparency | Bilateral / opaque | Real-time oracle | Dealer quotation | Stock price only |
| Intermediaries | Multiple dealers | None (P2P) | Multiple dealers | Broker |
PLATFORM
Building Financial Infrastructure for the Element That Is Rewriting Surgical Standards
Thulium has never had financial infrastructure because its market has been too small, too concentrated, and too specialized for traditional institutions to recognize as an asset class. Four tonnes of annual production, 91% from a single country, 85% consumed by a single application sector, traded through personal dealer relationships with no public benchmark. No contracts. No exchange listings. No settlement standards. No collateral frameworks. Every feature of the Toto Finance platform for thulium was designed to create what the medical rare earth market has never built: independent financial infrastructure for an element whose clinical importance is growing exponentially while its market infrastructure remains at zero.
Physical Backing with Medical-Application-Grade Delivery Capability
Every thulium token connects to verified thulium oxide (Tm₂O₃, 99.9%+) in insured custody. Request physical delivery and receive material ready for medical fiber laser doping, Tm-170 radioisotope target fabrication, Tm:YAG crystal growth, or superconductor compound synthesis. In a market where thulium has traded through dealer handshakes with no standardized delivery specification, on-chain proof-of-reserves creates the first continuously verifiable record of medical-grade thulium holdings with guaranteed purity.
Price Discovery for an Element That Has Never Had a Public Price
Thulium has never had a transparent price visible to the market. Specialty dealers quote bilaterally, vary pricing by customer relationship and order size, and adjust with Chinese production quotas rather than international demand signals. Toto Finance's oracle feeds and on-chain trading activity create the first public, real-time thulium pricing mechanism: independently verifiable, reflective of surgical laser demand and heavy rare earth fractionation output, and accessible to every market participant rather than confined to dealer telephone negotiations.
Instant Settlement for a Material Where Weeks of Delay Mean Surgical Systems Unbuilt
Traditional thulium procurement operates through specialty dealers with settlement timelines of one to three weeks, limited inventory, and logistics chains not designed for the urgency of medical device manufacturing schedules. Token settlement creates instant procurement capability, settling T+0 with stablecoins. For a surgical laser manufacturer whose quarterly production capacity is constrained by thulium availability, instant settlement is not a convenience improvement. It is the difference between shipping laser systems to hospitals or sending apologies.
Compliance for Medical Material Supply Chain Transactions
Thulium entering medical device manufacturing is subject to FDA supply chain documentation requirements, critical mineral sourcing regulations, and quality management system traceability mandates that govern materials incorporated into Class II and Class III surgical devices. Smart contracts embed KYC/AML verification, transfer restrictions, and jurisdiction-specific compliance rules directly into token architecture, creating a compliance layer designed for a material that transitions from commodity to medical device component.
Financial Tools for a Market That Has Never Had a Single Instrument
Lending, borrowing, hedging, and collateral management for thulium as a standalone asset: capabilities that have never existed because thulium's market has been invisible to the financial system. Smart contract protocols enable yield generation from thulium positions, stablecoin borrowing against holdings, and programmable hedging strategies built for an element whose 32%-growth demand curve, 4.2-tonne production base, and single-country concentration create risk dynamics that no existing commodity instrument captures.
Multi-Chain Presence
Tokenized thulium is deployed across Ethereum, Polygon, Cardano, Solana, and XRP Ledger. Medical device procurement platforms, institutional custodians, DeFi protocols, and individual holders can interact with thulium tokens on whatever chain infrastructure their operations already use. No migration required, no ecosystem lock-in, no chain-specific constraints on the rare earth element reshaping minimally invasive surgery.
QUESTIONS
Tokenized Thulium FAQ
Direct answers about tokenized thulium, In-Ground Thulium, medical fiber lasers, portable X-ray systems, and how Toto Finance provides the first open market access to the element behind the fastest-growing surgical technology in urology.
THIS IS WHY
450,000 Surgeries a Year Run on an Element the World Produces at 4.2 Tonnes. The Gap Is Widening.
The world needs 21 tonnes of thulium by 2030. Heavy rare earth fractionation will deliver 12.5. The 8.5-tonne deficit is not a market cycle. It is the arithmetic of a 0.007% ore concentration colliding with the fastest-growing surgical technology adoption curve in modern urology. Every fiber laser system shipped to a hospital contains 30 to 80 grams of an element whose total global production would fit in a car trunk. Every quarter, more surgical suites adopt thulium lasers because patient outcomes demand it. And every quarter, the gap between clinical demand and material reality widens. Toto Finance is building the infrastructure to bring the surgeon's element to an open, transparent, instant-settlement market for the first time.
Get Early Access